The prognosis in myasthenia gravis is very variable. The use of immunosuppressive drugs has steadily improved outcome in recent years.
Remission or substantial improvement can be expected in 80% of patients. For those with associated thymoma, the 5 year survival is approximately 30 %.
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page